Chandraditya Chakraborty, Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Uterine Cervical Neoplasms | 8 | 2018 | 2002 | 1.150 |
Why?
|
| Cervix Uteri | 2 | 2017 | 584 | 0.860 |
Why?
|
| Gene Expression Regulation, Neoplastic | 7 | 2021 | 8439 | 0.580 |
Why?
|
| Von Hippel-Lindau Tumor Suppressor Protein | 1 | 2018 | 300 | 0.550 |
Why?
|
| Genes, p16 | 1 | 2016 | 158 | 0.530 |
Why?
|
| Retinoblastoma Binding Proteins | 1 | 2016 | 95 | 0.530 |
Why?
|
| Multiple Myeloma | 5 | 2024 | 5120 | 0.470 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2018 | 621 | 0.470 |
Why?
|
| beta Catenin | 1 | 2017 | 1043 | 0.410 |
Why?
|
| DNA Methylation | 5 | 2018 | 4323 | 0.340 |
Why?
|
| Neoplasm Proteins | 2 | 2020 | 3606 | 0.330 |
Why?
|
| Human papillomavirus 16 | 4 | 2015 | 266 | 0.320 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2018 | 2868 | 0.300 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2018 | 3471 | 0.280 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2016 | 1876 | 0.280 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2016 | 2806 | 0.260 |
Why?
|
| Uterine Cervical Dysplasia | 3 | 2015 | 382 | 0.260 |
Why?
|
| Receptors, Cell Surface | 1 | 2014 | 2820 | 0.250 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2024 | 5187 | 0.220 |
Why?
|
| Promoter Regions, Genetic | 5 | 2018 | 5793 | 0.210 |
Why?
|
| HeLa Cells | 2 | 2018 | 3098 | 0.190 |
Why?
|
| 14-3-3 Proteins | 1 | 2020 | 221 | 0.170 |
Why?
|
| Ubiquitin-Conjugating Enzymes | 1 | 2019 | 198 | 0.160 |
Why?
|
| Ecosystem | 1 | 2022 | 483 | 0.160 |
Why?
|
| Chromatin Assembly and Disassembly | 1 | 2022 | 630 | 0.150 |
Why?
|
| Papillomavirus Infections | 3 | 2015 | 1600 | 0.150 |
Why?
|
| Evolution, Molecular | 2 | 2023 | 1884 | 0.130 |
Why?
|
| Genomics | 3 | 2023 | 5748 | 0.130 |
Why?
|
| Prognosis | 2 | 2021 | 29423 | 0.120 |
Why?
|
| Oligopeptides | 1 | 2020 | 1186 | 0.120 |
Why?
|
| Ubiquitin | 1 | 2019 | 833 | 0.120 |
Why?
|
| Adenocarcinoma | 2 | 2023 | 6312 | 0.120 |
Why?
|
| Sulfonamides | 1 | 2024 | 1972 | 0.120 |
Why?
|
| Genomic Instability | 3 | 2024 | 693 | 0.120 |
Why?
|
| Oncogene Proteins, Viral | 2 | 2015 | 341 | 0.110 |
Why?
|
| Alphapapillomavirus | 1 | 2016 | 218 | 0.110 |
Why?
|
| Neoplasm Staging | 3 | 2018 | 11105 | 0.110 |
Why?
|
| Cell Transformation, Viral | 1 | 2015 | 526 | 0.110 |
Why?
|
| Gene Expression Regulation, Viral | 2 | 2015 | 438 | 0.110 |
Why?
|
| Epithelium | 1 | 2017 | 1610 | 0.110 |
Why?
|
| Bone Marrow | 1 | 2022 | 2902 | 0.100 |
Why?
|
| DNA Copy Number Variations | 2 | 2018 | 2012 | 0.100 |
Why?
|
| Cell Line, Tumor | 5 | 2024 | 16793 | 0.100 |
Why?
|
| Papillomavirus E7 Proteins | 1 | 2011 | 112 | 0.100 |
Why?
|
| Antineoplastic Agents | 2 | 2024 | 13577 | 0.090 |
Why?
|
| Esophageal Neoplasms | 1 | 2021 | 1643 | 0.090 |
Why?
|
| Tumor Microenvironment | 1 | 2022 | 3770 | 0.090 |
Why?
|
| Mutation | 3 | 2021 | 29807 | 0.080 |
Why?
|
| Interleukin-1beta | 1 | 2015 | 998 | 0.080 |
Why?
|
| Immunotherapy | 1 | 2024 | 4611 | 0.080 |
Why?
|
| DNA, Viral | 1 | 2015 | 2182 | 0.080 |
Why?
|
| Gene Regulatory Networks | 1 | 2016 | 1721 | 0.070 |
Why?
|
| Survival Rate | 2 | 2021 | 12782 | 0.070 |
Why?
|
| Phosphorylation | 1 | 2016 | 8321 | 0.060 |
Why?
|
| Repressor Proteins | 2 | 2015 | 2974 | 0.060 |
Why?
|
| Epigenesis, Genetic | 2 | 2015 | 3720 | 0.060 |
Why?
|
| Humans | 15 | 2024 | 755533 | 0.050 |
Why?
|
| Tumor Cells, Cultured | 2 | 2021 | 6140 | 0.050 |
Why?
|
| Female | 10 | 2021 | 387920 | 0.050 |
Why?
|
| Melphalan | 1 | 2024 | 420 | 0.050 |
Why?
|
| Chromosomal Instability | 1 | 2023 | 176 | 0.050 |
Why?
|
| Deoxyribonucleases | 1 | 2023 | 213 | 0.050 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2016 | 4016 | 0.050 |
Why?
|
| India | 2 | 2015 | 2326 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2024 | 1396 | 0.040 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2023 | 2496 | 0.040 |
Why?
|
| Mice, SCID | 1 | 2021 | 2617 | 0.030 |
Why?
|
| Cell Cycle | 1 | 2023 | 2932 | 0.030 |
Why?
|
| Genes, Neoplasm | 1 | 2016 | 372 | 0.030 |
Why?
|
| Chromosomes, Human | 1 | 2016 | 445 | 0.030 |
Why?
|
| Human papillomavirus 18 | 1 | 2015 | 126 | 0.030 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2023 | 2822 | 0.030 |
Why?
|
| Virus Integration | 1 | 2015 | 297 | 0.030 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2021 | 3575 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 1 | 2021 | 6121 | 0.030 |
Why?
|
| Pyrimidines | 1 | 2024 | 2990 | 0.020 |
Why?
|
| Asymptomatic Diseases | 1 | 2015 | 570 | 0.020 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2015 | 1341 | 0.020 |
Why?
|
| Open Reading Frames | 1 | 2011 | 813 | 0.020 |
Why?
|
| Aged | 3 | 2015 | 167376 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2016 | 15682 | 0.020 |
Why?
|
| Disease Progression | 2 | 2015 | 13427 | 0.020 |
Why?
|
| Middle Aged | 3 | 2015 | 218055 | 0.020 |
Why?
|
| Host-Pathogen Interactions | 1 | 2015 | 1445 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2021 | 10392 | 0.020 |
Why?
|
| Mice | 2 | 2023 | 80745 | 0.020 |
Why?
|
| Apoptosis | 1 | 2021 | 9452 | 0.020 |
Why?
|
| Cell Line | 1 | 2015 | 15647 | 0.010 |
Why?
|
| Animals | 2 | 2023 | 167149 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2016 | 19987 | 0.010 |
Why?
|
| Prevalence | 1 | 2015 | 15589 | 0.010 |
Why?
|
| DNA-Binding Proteins | 1 | 2015 | 9561 | 0.010 |
Why?
|
| Inflammation | 1 | 2015 | 10717 | 0.010 |
Why?
|
| Male | 2 | 2023 | 356577 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2015 | 17703 | 0.010 |
Why?
|
| Adult | 2 | 2015 | 217986 | 0.010 |
Why?
|